Dataset opportunity
Kardium — 医疗影像数据集机会
Kardium 持有的中等规模医疗影像数据集，可用于诊断人工智能和计算机视觉。
Score
70.3
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market
全球诊断人工智能市场 = 2023 年为 12 亿美元，复合年增长率为 24.6%（来源：Grand View Research）
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-07-31
J&J’s robotics R&D head discusses Ottava’s folding arms, soothing sounds and haptics capability
medicaldesignandoutsourcing.com ↗ - 📰press2026-07-31
Siemens Healthineers, Cleveland Clinic form 10-year alliance
medtechdive.com ↗ - 📰press2026-07-31
Johnson & Johnson bets on in vivo CAR-T with Sail Biomedicines
nordiclifescience.org ↗ - 📰press2026-07-31
GP workforce gap healing in rural Queensland
medicalrepublic.com.au ↗ - 📰press2026-07-30
"Fake podiatrist" to serve two-year jail sentence in the community following appeal
hospitalhealth.com.au ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
医疗影像数据集
Modality
图像
Sector
医疗保健
Volume
中等
Freshness
实时
Rarity
高（专有）
Accessibility
受限
Legal
公司所有 — GDPR 敏感（个人身份信息审查）
Buyer persona
医疗人工智能与诊断影像公司
Kardium 持有一个独特的医疗影像数据集，该数据集源自其专有的 122 导联标测和消融系统。该数据集包含高度详细、敏感的患者电生理记录，包括心腔内电图和 3D 心脏图，这对于训练和验证用于房颤等复杂心律失常的先进诊断人工智能模型至关重要。
全球诊断人工智能市场在 2023 年的估值为 12 亿美元，预计将以 24.6% 的复合年增长率增长，显示出巨大的商业价值。尽管由于患者隐私和医疗器械法规导致访问复杂，但该数据集的专有数据极其稀有。其专业来源为旨在开发高增长心脏病学领域下一代诊断工具的人工智能开发者提供了显著的竞争优势。⚠ 尽职调查（有价值的数据，可协商访问）：数据涉及敏感的患者电生理记录；受严格的医疗器械法规和临床试验隐私的约束；专有数据通过专用的 122 导联硬件生成 · 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明 Kardium 拥有一个稀有的专有数据集，该数据集源自用于房颤（AF）治疗的正式临床试验。该数据独特地结合了医疗影像与其 122 导联诊断和消融系统的高清同步传感器数据。对于开发诊断人工智能的公司而言，这个多模态数据集是训练下一代房颤检测、手术指导和结果预测算法的关键资产，目标是快速增长的 12 亿美元诊断人工智能市场。
See dimension details ↓- Dataset Specificity90
主导的“医疗记录”，医疗保健行业，3 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
实时/流式传输
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
适用于诊断人工智能
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
人工智能买家需求极高，这得益于诊断人工智能市场 24.6% 的爆炸式复合年增长率，因为公司寻求专有数据以获得竞争优势。
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
个人身份信息/受监管
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
高难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 种证据类型，3 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
所有权=已拥有，许可=GDPR 敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2 个数据胃口信号（2 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高，5 个近期外部信号 — 已货币化的专有数据之外
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit92
✓ 良好目标 — 这家医疗器械公司的核心业务是销售用于治疗房颤的 Globe System；在手术过程中生成的高清心脏标测数据是有价值的、未货币化的副产品，使其成为一个理想的目标。问题：该公司资金充足，正快速增长，有望进行首次公开募股（IPO），与规模较小的公司相比，其对数据合作的兴趣可能会降低。
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
IoT / sensor data
这些证据表明来自设备 122 导联的高分辨率时间序列数据，捕获了详细的心脏标测和接触传感信息，对于训练自动诊断人工智能模型很有价值。
Medical records / imaging
这证实了数据集包含在严格的临床试验方案（PULSAR 和 GLOBAL 研究）下收集的医疗影像和相关记录，为验证人工智能诊断工具提供了监管级别的基础。
Industrial data
这指向了详细说明治疗过程本身的时间序列数据，包括消融能量和温度，这对于开发能够预测治疗效果并优化手术结果的人工智能至关重要。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
A teaser is generated for each dataset opportunity. The full report is available on unlock.
From the marketplace
Explore live data opportunities
Earth Ai — 大型数据资产机会
View opportunity →其他Renewablesfirst — 检验报告数据集机会
View opportunity →工业Sml Group — 地理空间数据集机会
View opportunity →